InnovaRx Innova Health Strategies

R76.0

Raised antibody titer

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 13 never code together
R76.0code
Excludes1
R70-R79block
Excludes2
  • abnormal findings on antenatal screening of mother (O28.-)O28.-
  • abnormalities of lipids (E78.-)E78.-
  • abnormalities of platelets and thrombocytes (D69.-)D69.-
  • abnormalities of white blood cells classified elsewhere (D70-D72)D70-D72
  • coagulation hemorrhagic disorders (D65-D68)D65-D68
  • diagnostic abnormal findings classified elsewhere - see Alphabetical Index
  • hemorrhagic and hematological disorders of newborn (P50-P61)P50-P61
R00-R99chapter
Excludes2
  • abnormal findings on antenatal screening of mother (O28.-)O28.-
  • certain conditions originating in the perinatal period (P04-P96)P04-P96
  • signs and symptoms classified in the body system chapters
  • signs and symptoms of breast (N63, N64.5)N63N64.5

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 9
R00-R99chapter
Notes
  • This chapter includes symptoms, signs, abnormal results of clinical or other investigative procedures, and ill-defined conditions regarding which no diagnosis classifiable elsewhere is recorded.
  • Signs and symptoms that point rather definitely to a given diagnosis have been assigned to a category in other chapters of the classification. In general, categories in this chapter include the less well-defined conditions and symptoms that, without the necessary study of the case to establish a final diagnosis, point perhaps equally to two or more diseases or to two or more systems of the body. Practically all categories in the chapter could be designated 'not otherwise specified', 'unknown etiology' or 'transient'. The Alphabetical Index should be consulted to determine which symptoms and signs are to be allocated here and which to other chapters. The residual subcategories, numbered .8, are generally provided for other relevant symptoms that cannot be allocated elsewhere in the classification.
  • The conditions and signs or symptoms included in categories R00-R94 consist of:R00-R94
  • (a) cases for which no more specific diagnosis can be made even after all the facts bearing on the case have been investigated;
  • (b) signs or symptoms existing at the time of initial encounter that proved to be transient and whose causes could not be determined;
  • (c) provisional diagnosis in a patient who failed to return for further investigation or care;
  • (d) cases referred elsewhere for investigation or treatment before the diagnosis was made;
  • (e) cases in which a more precise diagnosis was not available for any other reason;
  • (f) certain symptoms, for which supplementary information is provided, that represent important problems in medical care in their own right.
Index entries leading here 5
  • Antibody
    • antiphosphatidylglycerol R76.0
    • anticardiolipin R76.0
    • antiphosphatidylinositol R76.0
    • antiphosphatidylserine R76.0
    • antiphospholipid R76.0
  • Raised — see also Elevated
  • Elevated, elevation
  • Findings, abnormal, inconclusive, without diagnosis — see also Abnormal
    • antibody titer, elevated R76.0
    • anticardiolipin antibody R76.0
    • antiphosphatidylglycerol antibody R76.0
    • antiphosphatidylinositol antibody R76.0
    • antiphosphatidylserine antibody R76.0
    • antiphospholipid antibody R76.0
  • Lupus
    • anticoagulant D68.62
      • finding without diagnosis R76.0
    • erythematosus (discoid) (local) L93.0
Alongside this code 3 same parent — R76
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
R76
Block
R70-R79
Siblings
3

Present FY2024–FY2027.